Organization TC 1600 Bldg./Room RI UNITED STATES PATENT AND TRADEMARK OFFICE

PO. Box 1450 Alexandria, VA. 22313-1450 If Undeliverable Return In Ten Days

Official Business
Penalty For Private Use, \$300

AN EQUAL OPPORTUNITY EMPLOYER



MAY 0 4 2004 RECEIVED

TECH CENTER 1600/2900

98 695889056

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

26619

7590

04/19/2004

DELTAGEN, INC. 740 BAY ROAD REDWOOK CITY, CA 94063 EXAMINER

SULLIVAN, DANIEL M

ART UNIT

PAPER NUMBER

1636

DATE MAILED: 04/19/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/904 180	07/11/2001	Keith D. Allen	R-477	1187	

TITLE OF INVENTION: TRANSGENIC MICE CONTAINING STEFIN HOMOLOG PROTEASE INHIBITOR GENE DISRUPTIONS

1	APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
١	nonprovisional	YES	\$665	\$300	\$965	07/19/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

- A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.
- B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

- A. Pav TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
- □ Applicant claims SMALL ENTITY status. See 37 CFR 1.27.
- II. PART B FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax

(703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where

appropriate. All further comindicated unless corrected be maintenance fee notification	elow or directed otherwise	Patent, advance orders and in Block 1, by (a) speci	d notification of fying a new corre	maintenance fees v spondence address	will be mailed to the current; and/or (b) indicating a sepa	correspondence address as arate "FEE ADDRESS" for
	E ADDRESS (Note: Legibly mark-up	with any corrections or use Bloc	Fe	e(s) Transmittal. Th	mailing can only be used for his certificate cannot be used to al paper, such as an assignment	for any other accompanying
26619 75	90 04/19/2004		pa _l hav	e its own certificat	e of mailing or transmission.	on or rounds and mig, must
DELTAGEN, INC 740 BAY ROAD REDWOOK CITY			I h Sta ade tra	ereby certify that the tes Postal Service Iressed to the Ma	rtificate of Mailing or Trans his Fee(s) Transmittal is bein with sufficient postage for fir il Stop ISSUE FEE address PTO, on the date indicated bel	g deposited with the United st class mail in an envelope above, or being facsimile
			Γ			(Depositor's name)
						(Signature)
						(Date)
APPLICATION NO.	FILING DATE	FIRST	NAMED INVENTO	R	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,180	07/11/2001	I	Ceith D. Allen		R-477	1187
·	RANSGENIC MICE CONT	AINING STEFIN HOMO	OLOG PROTEAS	E INHIBITOR GE	NE DISRUPTIONS	
ITILE OF INVENTION: IT	KANSOLINE MICE CONT	in in o bibling in the interest				
APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBL	ICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$665		\$300	\$965	07/19/2004
EXAM	IINER	ART UNIT	CLAS	S-SUBCLASS	7	
SULLIVAN	DANIEL M	1636	80	00-018000	•	•
CFR 1.363). Change of correspond. Address form PTO/SB/1: "Fee Address" indicati	e address or indication of "Fence address (or Change of C 22) attached. ion (or "Fee Address" Indica or more recent) attached. Us	Correspondence age firm age age atto	nes of up to 3 ents OR, alternation (having as a ment) and the name	e patent front page registered patent a rely, (2) the name ember a registered s of up to 2 regist If no name is lister	of a single attorney or 2tered patent	
3. ASSIGNEE NAME AND PLEASE NOTE: Unless been previously submitte (A) NAME OF ASSIGN		low, no assignee data wi submitted under separate	II appear on the pa cover. Completion	ype) atent. Inclusion of a of this form is NO and STATE OR CO	assignee data is only appropri T a substitute for filing an ass DUNTRY)	ate when an assignment has signment.
Please check the appropriate	e assignee category or catego	ories (will not be printed o	on the patent);	🗆 individual 🚨	corporation or other private g	roup entity
4a. The following fee(s) are	enclosed:		nent of Fee(s):			÷
☐ Issue Fee				nt of the fee(s) is er rd. Form PTO-203		
☐ Publication Fee ☐ Advance Order - # of	Conies				charge the required fee(s), or	credit any overpayment, to
	·	Depo	sit Account Numb	er	(enclose an extra e	copy of this form).
Director for Patents is reque	ested to apply the issue ree a	ind Fublication Fee (if an	y) of to re-appry a	ny previousiy paid	issue fee to the approximation	
(Authorized Signature)		(Date)				
other than the applicant; interest as shown by the re	d Publication Fee (if require a registered attorney or agecords of the United States P	atent and Trademark Offi	ce.			
This collection of informobtain or retain a benefit application. Confidentialit estimated to take 12 minu completed application for case. Any comments on suggestions for reducing Patent and Trademark 23313, 1450, DO NOT	ation is required by 37 CFF by the public which is to by is governed by 35 U.S.C. ates to complete, including grm to the USPTO. Time withe amount of time you this burden, should be sent Office, U.S. Department SEND FEES OR COMPLIF for Patents, Alexandria, Vi	1.311. The information file (and by the USPTO 122 and 37 CFR 1.14. The athering, preparing, and ill vary depending upon require to complete this to the Chief Information of Commerce, Alexan CTED FORMS TO THI	is required to to process) an is collection is submitting the			



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	D.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/904,180		07/11/2001	Keith D. Allen	R-477	1187	
26619	7590	04/19/2004		EXAM	INER	
DELTAGEN, INC.				SULLIVAN, DANIEL M		
740 BAY ROAD REDWOOK CITY, CA 94063		94063		ART UNIT	PAPER NUMBER	
,				1636		
				DATE MAILED: 04/19/200-	4	

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

•			
	Application No.	Applicant(s)	
Nation of Allowability	09/904,180	ALLEN, KEITH D.	
Notice of Allowability	Examiner	Art Unit	
	Daniel M Sullivan	1636	
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS erewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate comministry of the commini	n this application. If not included unication will be mailed in due course. THIS subject to withdrawal from issue at the initia	
. Mail This communication is responsive to the Amendment and the second	Request for Continued Exai	nination filed 9 January 2004.	
 ∴ The allowed claim(s) is/are <u>1-5,8-11,20,22 and 24</u>. 			
3. \boxtimes The drawings filed on <u>28 October 2002</u> are accepted by the	e Examiner.	•	
Acknowledgment is made of a claim for foreign priority una a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	e been received. e been received in Application cuments have been received of this communication to file IENT of this application. itted. Note the attached EXA	n No d in this national stage application from the a reply complying with the requirements AMINER'S AMENDMENT or NOTICE OF	,
CORRECTED DRAWINGS (as "replacement sheets") mus (a) ☐ including changes required by the Notice of Draftspers 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner's	on's Patent Drawing Reviev	,	
Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the	.84(c)) should be written on t he header according to 37 CF	ne drawings in the front (not the back) of R 1.121(d).	
DEPOSIT OF and/or INFORMATION about the depo- attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MAT	ERIAL must be submitted. Note the	
Attachment(s) . Notice of References Cited (PTO-892) . Notice of Draftperson's Patent Drawing Review (PTO-948) . Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date Examiner's Comment Regarding Requirement for Deposit	6. ☐ Interview S Paper No. 98), 7. ☑ Examiner's	formal Patent Application (PTO-152) ummary (PTO-413), Mail Date Amendment/Comment Statement of Reasons for Allowance	
of Biological Material	9. Other		
		Anne-Marie Jalk ANNE-MARIE FALK, PH.D PRIMARY EXAMINER	2

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04) Application/Control Number: 09/904,180

Art Unit: 1636

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Robert Driscoll on 1 April 2004.

The application has been amended as follows:

Claims 9 and 10 have been replaced with the following amended claims:

- 9. A cell derived isolated from the transgenic mouse of claim 8.
- 10. A method of producing a transgenic mouse comprising a genome comprising a disruption in an endogenous stefin homolog gene comprising SEQ ID NO: 1, the method comprising:
 - (a) introducing the targeting construct of claim 1 into a mouse embryonic stem cell;
 - (b) selecting a cell which has undergone homologous recombination;
 - (c) introducing the cell into a blastocyst;
 - (e)(d) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
 - (d)(e) breeding the chimeric mouse to produce the transgenic mouse wherein where the disruption is homozygous, the transgenic mouse lacks production of functional protein encoded by the stefin homolog gene and exhibits, relative to a wild-type mouse, a

Application/Control Number: 09/904,180

Art Unit: 1636

phenotype selected from the group consisting of: increased activity, schizophrenic behavior, and decreased propensity for despair or depression.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 571-272-0779. The examiner can normally be reached on Monday through Thursday 6:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DMS

NNE-MARIE FALK, PH.D.
PRIMARY EXAMINED

Anne-Marie Falk

*	Application No.	Applicant(s)
- Little Alberta minus Summans	09/904,180	ALLEN, KEITH D.
Examiner-Initiated Interview Summary	Examiner	Art Unit
	Daniel M Sullivan	1636
All Participants:	Status of Application: <u>All</u>	owed
(1) <u>Daniel M Sullivan</u> .	(3)	
(2) Robert Driscoll.	(4)	!
Date of Interview: <u>1 April 2004</u>	Time:	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ App	licant's representative)	
Exhibit Shown or Demonstrated: Yes No If Yes, provide a brief description:		
Part I.		
Rejection(s) discussed:		
Claims discussed: 9, 10		
3, 10		
Prior art documents discussed:		
Down II		
Part II. SUBSTANCE OF INTERVIEW DESCRIBING THE GE	NERAL NATURE OF WHAT WA	AS DISCUSSED:
CODOTANGE OF INVERVIEW BEGONDERS WE SE		
Part III.		
 ☑ It is not necessary for applicant to provide a separal directly resulted in the allowance of the application. of the interview in the Notice of Allowability. ☐ It is not necessary for applicant to provide a separal did not result in resolution of all issues. A brief summer 	The examiner will provide a wri	tten summary of the substance e interview, since the interview
Anne-Marie Talk		
ANNE-MARIE FALK, PH.D PRIMARY EXAMINED		
(Examiner/SPE Signature) (Applic	cant/Applicant's Representative	Signature – if appropriate)